rabbit anti cfos Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Santa Cruz Biotechnology rabbit anti cfos cfos
    Acute corneal injury induces activation of presympathetic neurons <t>coexpressing</t> <t>NK1R</t> in the PVH and LHA. ( A ) Activated presympathetic neurons <t>(cFOS</t> + and TH + ) that expressed NK1R were assessed by immunofluorescence. Representative images (20×) of WT ( n = 3) and TAC1-KO ( n = 4) mice after bilateral corneal alkali burn. Triple-positive neurons are shown with arrowheads . ( B ) Quantification of triple-positive neurons expressed as a percentage over the total number of TH + neurons in the PVH and the LHA. TAC1-KO mice showed a decreased activation of sympathetic neurons coexpressing NK1R. Graphs represent mean ± SEM; statistical analysis by Mann–Whitney test. * P < 0.05. Scale bar : 25 µm.
    Rabbit Anti Cfos Cfos, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cfos cfos/product/Santa Cruz Biotechnology
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cfos cfos - by Bioz Stars, 2024-07
    99/100 stars
      Buy from Supplier

    86
    Millipore rabbit anti cfos
    Acute corneal injury induces activation of presympathetic neurons <t>coexpressing</t> <t>NK1R</t> in the PVH and LHA. ( A ) Activated presympathetic neurons <t>(cFOS</t> + and TH + ) that expressed NK1R were assessed by immunofluorescence. Representative images (20×) of WT ( n = 3) and TAC1-KO ( n = 4) mice after bilateral corneal alkali burn. Triple-positive neurons are shown with arrowheads . ( B ) Quantification of triple-positive neurons expressed as a percentage over the total number of TH + neurons in the PVH and the LHA. TAC1-KO mice showed a decreased activation of sympathetic neurons coexpressing NK1R. Graphs represent mean ± SEM; statistical analysis by Mann–Whitney test. * P < 0.05. Scale bar : 25 µm.
    Rabbit Anti Cfos, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cfos/product/Millipore
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cfos - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Synaptic Systems rabbit anti cfos
    (A) Viral constructs and implantation coordinates. Representative image showing ChR2 expression and fiber placement. Scale bar: 200 μm. (B) Schematic illustrating the experimental design. (C) Representative images showing ChR2, <t>cFos</t> and double positive cells (top) <t>or</t> <t>EYFP,</t> cFos and double positive cells in ChR2 and Ctrl females, respectively. Scale bars: 100 μm. (D) Quantification of percentage of AAV+ cells that are double positive for cFos in Ctrl versus ChR2 females. * represents p<0.05 using Mann-Whitney U test. (E) Left: Representative trace from a ChR2 transfected aVMHvl Pr+ neuron recorded in current clamp mode and being stimulated with 20 ms pulses of blue light (5mW) at 20Hz for 5 seconds. Right: Spike fidelity (spikes measured/ number of light pulses delivered) for the individual aVMHvl Pr+ neurons recorded. (F) Percentage of females that had sex within 30 minutes after the first mount attempt by the male.* represents p<0.05 using the Z test. (G). Comparison of various behaviors displayed by Ctrl and ChR2 females during the appetitive 1 phase. * represents p<0.05 using Mann-Whitney U test. (H). Comparison of various behaviors displayed by Ctrl and ChR2 females during the appetitive 2 phase. 1 Ctrl and 1 ChR2 female did not have an App2 phase, i.e., the first mount attempt led to a successful mount with thrusts. * represents p<0.05 using Mann-Whitney U test. (I). Comparison of various behaviors displayed by Ctrl and ChR2 females during the consummatory phase. * represents p<0.05 using Mann-Whitney U test. (J) Top: Velocity profiles for the male (red) and female (blue) and the corresponding difference in distance over time between the couple (black) around a fight event (solid line) for females in the ChR2 group and D females from the photometry experiment. Shaded error bars indicate mean and standard error across mice. Bottom: Binned distribution of male locations with respect to the female at the moment of fight.
    Rabbit Anti Cfos, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cfos/product/Synaptic Systems
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cfos - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Abcam rabbit anti cfos
    (A) Vehicle- and ML297-treated WT and Fmr1 -/y mice with ad lib sleep were perfused 90 min following CFM recall to assess <t>cFos</t> expression, parvalbumin (PV) interneuron density, and perineuronal net (PNN) activity. Representative recall-associated cFos (cyan), PV (magenta), <t>and</t> <t>wisteria</t> floribunda agglutinin (WFA; yellow) for PNN expression in DG for the four treatment groups. Scale bar = 100 µm ( top , whole DG); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of DG cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) = 0.88, p (genotype) = 0.082, p (treatment x genotype interaction) < 0.0001. For PV+ neurons: p (treatment) = 0.90, p (genotype) = 0.62, p (treatment x genotype interaction) = 0.06. For PNN: p (treatment) = 0.01, p (genotype) = 0.0002, p (treatment x genotype interaction) = 0.22. For cFos+PV co-localized neurons: p (treatment) < 0.0001, p (genotype) = 0.0001, p (treatment x genotype interaction) = 0.031. For PNN+PV co-localized neurons: p (treatment) = 0.32, p (genotype) = 0.098, p (treatment x genotype interaction) = 0.0026. (C) Quantification of DG percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) < 0.0001, p (genotype) = 0.056, p (treatment x genotype interaction) = 0.28. For % cFos+PV cells over total PV: p (treatment) < 0.0001, p (genotype) = 0.0005, p (treatment x genotype interaction) = 0.0061. For % PNN+PV cells over total PNN: p (treatment) = 0.21, p (genotype) = 0.096, p (treatment x genotype interaction) = 0.21. For % PNN+PV cells over total PV: p (treatment) = 0.16, p (genotype) = 0.13, p (treatment x genotype interaction) = 0.10. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in the entire DG vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM.
    Rabbit Anti Cfos, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cfos/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cfos - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Acute corneal injury induces activation of presympathetic neurons coexpressing NK1R in the PVH and LHA. ( A ) Activated presympathetic neurons (cFOS + and TH + ) that expressed NK1R were assessed by immunofluorescence. Representative images (20×) of WT ( n = 3) and TAC1-KO ( n = 4) mice after bilateral corneal alkali burn. Triple-positive neurons are shown with arrowheads . ( B ) Quantification of triple-positive neurons expressed as a percentage over the total number of TH + neurons in the PVH and the LHA. TAC1-KO mice showed a decreased activation of sympathetic neurons coexpressing NK1R. Graphs represent mean ± SEM; statistical analysis by Mann–Whitney test. * P < 0.05. Scale bar : 25 µm.

    Journal: Investigative Ophthalmology & Visual Science

    Article Title: A Hypothalamic-Controlled Neural Reflex Promotes Corneal Inflammation

    doi: 10.1167/iovs.62.13.21

    Figure Lengend Snippet: Acute corneal injury induces activation of presympathetic neurons coexpressing NK1R in the PVH and LHA. ( A ) Activated presympathetic neurons (cFOS + and TH + ) that expressed NK1R were assessed by immunofluorescence. Representative images (20×) of WT ( n = 3) and TAC1-KO ( n = 4) mice after bilateral corneal alkali burn. Triple-positive neurons are shown with arrowheads . ( B ) Quantification of triple-positive neurons expressed as a percentage over the total number of TH + neurons in the PVH and the LHA. TAC1-KO mice showed a decreased activation of sympathetic neurons coexpressing NK1R. Graphs represent mean ± SEM; statistical analysis by Mann–Whitney test. * P < 0.05. Scale bar : 25 µm.

    Article Snippet: The triple immunostaining was performed using chicken anti–tyrosine hydroxylase (TH) (1/800, AB76442; Abcam, Cambridge, UK), rabbit anti-cFOS (cFOS) (1/50, SC52; Santa Cruz Biotechnology, Dallas, Texas, USA), and goat anti-NK1R (1/800, AB61705; Abcam).

    Techniques: Activation Assay, Immunofluorescence, MANN-WHITNEY

    (A) Viral constructs and implantation coordinates. Representative image showing ChR2 expression and fiber placement. Scale bar: 200 μm. (B) Schematic illustrating the experimental design. (C) Representative images showing ChR2, cFos and double positive cells (top) or EYFP, cFos and double positive cells in ChR2 and Ctrl females, respectively. Scale bars: 100 μm. (D) Quantification of percentage of AAV+ cells that are double positive for cFos in Ctrl versus ChR2 females. * represents p<0.05 using Mann-Whitney U test. (E) Left: Representative trace from a ChR2 transfected aVMHvl Pr+ neuron recorded in current clamp mode and being stimulated with 20 ms pulses of blue light (5mW) at 20Hz for 5 seconds. Right: Spike fidelity (spikes measured/ number of light pulses delivered) for the individual aVMHvl Pr+ neurons recorded. (F) Percentage of females that had sex within 30 minutes after the first mount attempt by the male.* represents p<0.05 using the Z test. (G). Comparison of various behaviors displayed by Ctrl and ChR2 females during the appetitive 1 phase. * represents p<0.05 using Mann-Whitney U test. (H). Comparison of various behaviors displayed by Ctrl and ChR2 females during the appetitive 2 phase. 1 Ctrl and 1 ChR2 female did not have an App2 phase, i.e., the first mount attempt led to a successful mount with thrusts. * represents p<0.05 using Mann-Whitney U test. (I). Comparison of various behaviors displayed by Ctrl and ChR2 females during the consummatory phase. * represents p<0.05 using Mann-Whitney U test. (J) Top: Velocity profiles for the male (red) and female (blue) and the corresponding difference in distance over time between the couple (black) around a fight event (solid line) for females in the ChR2 group and D females from the photometry experiment. Shaded error bars indicate mean and standard error across mice. Bottom: Binned distribution of male locations with respect to the female at the moment of fight.

    Journal: bioRxiv

    Article Title: Cyclical control of female rejection behavior by progesterone receptor–expressing neurons of the anterior ventromedial hypothalamus

    doi: 10.1101/2023.01.30.526259

    Figure Lengend Snippet: (A) Viral constructs and implantation coordinates. Representative image showing ChR2 expression and fiber placement. Scale bar: 200 μm. (B) Schematic illustrating the experimental design. (C) Representative images showing ChR2, cFos and double positive cells (top) or EYFP, cFos and double positive cells in ChR2 and Ctrl females, respectively. Scale bars: 100 μm. (D) Quantification of percentage of AAV+ cells that are double positive for cFos in Ctrl versus ChR2 females. * represents p<0.05 using Mann-Whitney U test. (E) Left: Representative trace from a ChR2 transfected aVMHvl Pr+ neuron recorded in current clamp mode and being stimulated with 20 ms pulses of blue light (5mW) at 20Hz for 5 seconds. Right: Spike fidelity (spikes measured/ number of light pulses delivered) for the individual aVMHvl Pr+ neurons recorded. (F) Percentage of females that had sex within 30 minutes after the first mount attempt by the male.* represents p<0.05 using the Z test. (G). Comparison of various behaviors displayed by Ctrl and ChR2 females during the appetitive 1 phase. * represents p<0.05 using Mann-Whitney U test. (H). Comparison of various behaviors displayed by Ctrl and ChR2 females during the appetitive 2 phase. 1 Ctrl and 1 ChR2 female did not have an App2 phase, i.e., the first mount attempt led to a successful mount with thrusts. * represents p<0.05 using Mann-Whitney U test. (I). Comparison of various behaviors displayed by Ctrl and ChR2 females during the consummatory phase. * represents p<0.05 using Mann-Whitney U test. (J) Top: Velocity profiles for the male (red) and female (blue) and the corresponding difference in distance over time between the couple (black) around a fight event (solid line) for females in the ChR2 group and D females from the photometry experiment. Shaded error bars indicate mean and standard error across mice. Bottom: Binned distribution of male locations with respect to the female at the moment of fight.

    Article Snippet: Brain slices then underwent a double immunostaining for EYFP and cFos using a primary antibody cocktail of rabbit anti-cFos (1:2000, Synaptic Systems, Cat. No. 226 008) and goat anti-GFP (1:1000, Abcam, ab6673) followed by a secondary antibody cocktail of Alexa Fluor 594 donkey anti-rabbit (1:1000, Invitrogen, ab150076) and Alexa Fluor Plus 488 donkey anti-goat (1:1000, Invitrogen, A32814).

    Techniques: Construct, Expressing, MANN-WHITNEY, Transfection

    (A) Vehicle- and ML297-treated WT and Fmr1 -/y mice with ad lib sleep were perfused 90 min following CFM recall to assess cFos expression, parvalbumin (PV) interneuron density, and perineuronal net (PNN) activity. Representative recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in DG for the four treatment groups. Scale bar = 100 µm ( top , whole DG); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of DG cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) = 0.88, p (genotype) = 0.082, p (treatment x genotype interaction) < 0.0001. For PV+ neurons: p (treatment) = 0.90, p (genotype) = 0.62, p (treatment x genotype interaction) = 0.06. For PNN: p (treatment) = 0.01, p (genotype) = 0.0002, p (treatment x genotype interaction) = 0.22. For cFos+PV co-localized neurons: p (treatment) < 0.0001, p (genotype) = 0.0001, p (treatment x genotype interaction) = 0.031. For PNN+PV co-localized neurons: p (treatment) = 0.32, p (genotype) = 0.098, p (treatment x genotype interaction) = 0.0026. (C) Quantification of DG percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) < 0.0001, p (genotype) = 0.056, p (treatment x genotype interaction) = 0.28. For % cFos+PV cells over total PV: p (treatment) < 0.0001, p (genotype) = 0.0005, p (treatment x genotype interaction) = 0.0061. For % PNN+PV cells over total PNN: p (treatment) = 0.21, p (genotype) = 0.096, p (treatment x genotype interaction) = 0.21. For % PNN+PV cells over total PV: p (treatment) = 0.16, p (genotype) = 0.13, p (treatment x genotype interaction) = 0.10. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in the entire DG vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM.

    Journal: bioRxiv

    Article Title: Hypnotic treatment reverses NREM sleep disruption and EEG desynchronization in a mouse model of Fragile X syndrome to rescue memory consolidation deficits

    doi: 10.1101/2023.07.14.549070

    Figure Lengend Snippet: (A) Vehicle- and ML297-treated WT and Fmr1 -/y mice with ad lib sleep were perfused 90 min following CFM recall to assess cFos expression, parvalbumin (PV) interneuron density, and perineuronal net (PNN) activity. Representative recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in DG for the four treatment groups. Scale bar = 100 µm ( top , whole DG); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of DG cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) = 0.88, p (genotype) = 0.082, p (treatment x genotype interaction) < 0.0001. For PV+ neurons: p (treatment) = 0.90, p (genotype) = 0.62, p (treatment x genotype interaction) = 0.06. For PNN: p (treatment) = 0.01, p (genotype) = 0.0002, p (treatment x genotype interaction) = 0.22. For cFos+PV co-localized neurons: p (treatment) < 0.0001, p (genotype) = 0.0001, p (treatment x genotype interaction) = 0.031. For PNN+PV co-localized neurons: p (treatment) = 0.32, p (genotype) = 0.098, p (treatment x genotype interaction) = 0.0026. (C) Quantification of DG percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) < 0.0001, p (genotype) = 0.056, p (treatment x genotype interaction) = 0.28. For % cFos+PV cells over total PV: p (treatment) < 0.0001, p (genotype) = 0.0005, p (treatment x genotype interaction) = 0.0061. For % PNN+PV cells over total PNN: p (treatment) = 0.21, p (genotype) = 0.096, p (treatment x genotype interaction) = 0.21. For % PNN+PV cells over total PV: p (treatment) = 0.16, p (genotype) = 0.13, p (treatment x genotype interaction) = 0.10. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in the entire DG vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM.

    Article Snippet: Hippocampal and amygdala sections were then incubated overnight in primary antibody at 4°C: rabbit-anti-cFos (1:1000; Abcam, ab190289), mouse-anti-PV (1:2000; Millipore, MAB11572), and wisteria floribunda agglutinin (lectin) tagged with fluorescein (WFA; 1:500; Vector Labs, FL-1351-2).

    Techniques: Expressing, Activity Assay

    (A) Representative fear memory recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in CA1 for the four treatment groups. Scale bar = 250 µm ( top , whole CA1); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of CA1 cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) < 0.0001, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.21. For PV+ neurons: p (treatment) = 0.44, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.66. For PNN: p (treatment) = 0.039, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.033. For cFos+PV co-localized neurons: p (treatment) = 0.48, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.54. For PNN+PV co-localized neurons: p (treatment) = 0.0008, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.30. (C) Quantification of CA1 percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) = 0.018, p (genotype) = 0.0029, p (treatment x genotype interaction) = 0.38. For % cFos+PV cells over total PV: p (treatment) = 0.42, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.32. For % PNN+PV cells over total PNN: p (treatment) = 0.065, p (genotype) = 0.0004, p (treatment x genotype interaction) = 0.15. For % PNN+PV cells over total PV: p (treatment) = 0.026, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.67. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in CA1 vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM. (Related to )

    Journal: bioRxiv

    Article Title: Hypnotic treatment reverses NREM sleep disruption and EEG desynchronization in a mouse model of Fragile X syndrome to rescue memory consolidation deficits

    doi: 10.1101/2023.07.14.549070

    Figure Lengend Snippet: (A) Representative fear memory recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in CA1 for the four treatment groups. Scale bar = 250 µm ( top , whole CA1); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of CA1 cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) < 0.0001, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.21. For PV+ neurons: p (treatment) = 0.44, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.66. For PNN: p (treatment) = 0.039, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.033. For cFos+PV co-localized neurons: p (treatment) = 0.48, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.54. For PNN+PV co-localized neurons: p (treatment) = 0.0008, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.30. (C) Quantification of CA1 percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) = 0.018, p (genotype) = 0.0029, p (treatment x genotype interaction) = 0.38. For % cFos+PV cells over total PV: p (treatment) = 0.42, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.32. For % PNN+PV cells over total PNN: p (treatment) = 0.065, p (genotype) = 0.0004, p (treatment x genotype interaction) = 0.15. For % PNN+PV cells over total PV: p (treatment) = 0.026, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.67. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in CA1 vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM. (Related to )

    Article Snippet: Hippocampal and amygdala sections were then incubated overnight in primary antibody at 4°C: rabbit-anti-cFos (1:1000; Abcam, ab190289), mouse-anti-PV (1:2000; Millipore, MAB11572), and wisteria floribunda agglutinin (lectin) tagged with fluorescein (WFA; 1:500; Vector Labs, FL-1351-2).

    Techniques: Expressing

    (A) Representative fear memory recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in CA3 for the four treatment groups. Scale bar = 250 µm ( top , whole CA3); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of CA3 cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) = 0.30, p (genotype) = 0.21, p (treatment x genotype interaction) = 0.91. For PV+ neurons: p (treatment) = 0.68, p (genotype) = 0.018, p (treatment x genotype interaction) = 0.083. For PNN: p (treatment) = 0.32, p (genotype) = 0.0006, p (treatment x genotype interaction) = 0.0002. For cFos+PV co-localized neurons: p (treatment) = 0.23, p (genotype) = 0.21, p (treatment x genotype interaction) = 0.41. For PNN+PV co-localized neurons: p (treatment) = 0.86, p (genotype) = 0.0005, p (treatment x genotype interaction) = 0.0026. (C) Quantification of CA3 percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) = 0.093, p (genotype) = 0.14, p (treatment x genotype interaction) = 0.52. For % cFos+PV cells over total PV: p (treatment) = 0.044, p (genotype) = 0.95, p (treatment x genotype interaction) = 0.33. For % PNN+PV cells over total PNN: p (treatment) = 0.43, p (genotype) = 0.13, p (treatment x genotype interaction) = 0.79. For % PNN+PV cells over total PV: p (treatment) = 0.87, p (genotype) = 0.0014, p (treatment x genotype interaction) = 0.022. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in CA3 vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM. (Related to )

    Journal: bioRxiv

    Article Title: Hypnotic treatment reverses NREM sleep disruption and EEG desynchronization in a mouse model of Fragile X syndrome to rescue memory consolidation deficits

    doi: 10.1101/2023.07.14.549070

    Figure Lengend Snippet: (A) Representative fear memory recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in CA3 for the four treatment groups. Scale bar = 250 µm ( top , whole CA3); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of CA3 cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) = 0.30, p (genotype) = 0.21, p (treatment x genotype interaction) = 0.91. For PV+ neurons: p (treatment) = 0.68, p (genotype) = 0.018, p (treatment x genotype interaction) = 0.083. For PNN: p (treatment) = 0.32, p (genotype) = 0.0006, p (treatment x genotype interaction) = 0.0002. For cFos+PV co-localized neurons: p (treatment) = 0.23, p (genotype) = 0.21, p (treatment x genotype interaction) = 0.41. For PNN+PV co-localized neurons: p (treatment) = 0.86, p (genotype) = 0.0005, p (treatment x genotype interaction) = 0.0026. (C) Quantification of CA3 percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) = 0.093, p (genotype) = 0.14, p (treatment x genotype interaction) = 0.52. For % cFos+PV cells over total PV: p (treatment) = 0.044, p (genotype) = 0.95, p (treatment x genotype interaction) = 0.33. For % PNN+PV cells over total PNN: p (treatment) = 0.43, p (genotype) = 0.13, p (treatment x genotype interaction) = 0.79. For % PNN+PV cells over total PV: p (treatment) = 0.87, p (genotype) = 0.0014, p (treatment x genotype interaction) = 0.022. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in CA3 vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM. (Related to )

    Article Snippet: Hippocampal and amygdala sections were then incubated overnight in primary antibody at 4°C: rabbit-anti-cFos (1:1000; Abcam, ab190289), mouse-anti-PV (1:2000; Millipore, MAB11572), and wisteria floribunda agglutinin (lectin) tagged with fluorescein (WFA; 1:500; Vector Labs, FL-1351-2).

    Techniques: Expressing

    (A) Representative fear memory recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in the amygdala for the four treatment groups. Scale bar = 250 µm ( top , amygdala); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) = 0.12, p (genotype) = 0.018, p (treatment x genotype interaction) = 0.085. For PV+ neurons: p (treatment) = 0.98, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.77. For PNN: p (treatment) < 0.0001, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.01. For cFos+PV co-localized neurons: p (treatment) = 0.26, p (genotype) = 0.0088, p (treatment x genotype interaction) = 0.23. For PNN+PV co-localized neurons: p (treatment) < 0.0001, p (genotype) < 0.0001, p (treatment x genotype interaction) < 0.0001. (C) Quantification of percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) = 0.67, p (genotype) = 0.048, p (treatment x genotype interaction) = 0.66. For % cFos+PV cells over total PV: p (treatment) = 0.27, p (genotype) = 0.76, p (treatment x genotype interaction) = 0.77. For % PNN+PV cells over total PNN: p (treatment) = 0.0027, p (genotype) = 0.0013, p (treatment x genotype interaction) = 0.11. For % PNN+PV cells over total PV: p (treatment) < 0.0001, p (genotype) = 0.0026, p (treatment x genotype interaction) = 0.018. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in amygdala vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM. (Related to )

    Journal: bioRxiv

    Article Title: Hypnotic treatment reverses NREM sleep disruption and EEG desynchronization in a mouse model of Fragile X syndrome to rescue memory consolidation deficits

    doi: 10.1101/2023.07.14.549070

    Figure Lengend Snippet: (A) Representative fear memory recall-associated cFos (cyan), PV (magenta), and wisteria floribunda agglutinin (WFA; yellow) for PNN expression in the amygdala for the four treatment groups. Scale bar = 250 µm ( top , amygdala); scale bar = 30 µm ( bottom , inset of select neurons). (B) Quantification of cFos+, PV+, PNN, and co-localization neuronal density. Two-way ANOVA, for cFos+ neurons: p (treatment) = 0.12, p (genotype) = 0.018, p (treatment x genotype interaction) = 0.085. For PV+ neurons: p (treatment) = 0.98, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.77. For PNN: p (treatment) < 0.0001, p (genotype) < 0.0001, p (treatment x genotype interaction) = 0.01. For cFos+PV co-localized neurons: p (treatment) = 0.26, p (genotype) = 0.0088, p (treatment x genotype interaction) = 0.23. For PNN+PV co-localized neurons: p (treatment) < 0.0001, p (genotype) < 0.0001, p (treatment x genotype interaction) < 0.0001. (C) Quantification of percent co-localization of cFos+, PV+, and PNN over total neuronal populations. Two-way ANOVA, for % cFos+PV cells over total cFos: p (treatment) = 0.67, p (genotype) = 0.048, p (treatment x genotype interaction) = 0.66. For % cFos+PV cells over total PV: p (treatment) = 0.27, p (genotype) = 0.76, p (treatment x genotype interaction) = 0.77. For % PNN+PV cells over total PNN: p (treatment) = 0.0027, p (genotype) = 0.0013, p (treatment x genotype interaction) = 0.11. For % PNN+PV cells over total PV: p (treatment) < 0.0001, p (genotype) = 0.0026, p (treatment x genotype interaction) = 0.018. (D) Pearson correlation of cFos+, PV+, and PNN neuron densities and associated co-localizations in amygdala vs. associated change in freezing behavior during CFM recall. R and p values for Pearson correlation of each data set are found alongside corresponding graph. Sample sizes: n = 7 (WT+vehicle), n = 7 ( Fmr1 -/y +vehicle), n = 7 (WT+ML297), n = 8 ( Fmr1 -/y +ML297). *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, p < 0.0001; Tukey’s post hoc test. Data shown as mean ± SEM. (Related to )

    Article Snippet: Hippocampal and amygdala sections were then incubated overnight in primary antibody at 4°C: rabbit-anti-cFos (1:1000; Abcam, ab190289), mouse-anti-PV (1:2000; Millipore, MAB11572), and wisteria floribunda agglutinin (lectin) tagged with fluorescein (WFA; 1:500; Vector Labs, FL-1351-2).

    Techniques: Expressing